Reference : Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin ...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
http://hdl.handle.net/10993/18379
Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
English
Bonz, Andreas W. [> >]
Lengenfelder, Bjorn [> >]
Strotmann, Jorg [> >]
Held, Stefanie [> >]
Turschner, Oliver [> >]
Harre, Kerstin [> >]
Wacker, Christian [> >]
Waller, Christiane [> >]
Kochsiek, Nikolaus [> >]
Meesmann, Malte [> >]
Neyses, Ludwig mailto [University of Luxembourg > Research Office]
Schanzenbacher, Peter [> >]
Ertl, Georg [> >]
Voelker, Wolfram [> >]
2002
Journal of the American College of Cardiology
40
4
662-8
Yes (verified by ORBilu)
International
0735-1097
United States
[en] Angioplasty, Balloon, Coronary ; Aspirin/therapeutic use ; Coronary Disease/blood/therapy ; Double-Blind Method ; Drug Therapy, Combination ; Humans ; Platelet Aggregation Inhibitors/therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors ; Premedication ; Stents ; Surgical Procedures, Elective ; Ticlopidine/analogs & derivatives/therapeutic use ; Troponin T/secretion ; Tyrosine/analogs & derivatives/pharmacology/therapeutic use
[en] OBJECTIVES: The Troponin in Planned PTCA/Stent Implantation With or Without Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Tirofiban (TOPSTAR) trial investigated: 1) the amount of troponin T (TnT) release after nonacute, elective percutaneous coronary intervention (PCI) in patients pretreated with aspirin and clopidogrel; and 2) the effect of additional glycoprotein (GP) IIb/IIIa receptor inhibiton on postinterventional TnT release. BACKGROUND: No data are available yet as to whether additional administration of a GP IIb/IIIa receptor antagonist might be beneficial in patients undergoing elective PCI already pretreated with aspirin and clopidogrel. METHODS: After bolus application of the study medication (tirofiban [T] or placebo [P]), PCI was performed followed by an 18-h continuous infusion of T/P. Primary end point of the study was incidence and amount of TnT release after elective PCI after 24 h. RESULTS: A total of 12 h after PCI troponin release was detected in 63% of the patients receiving P and in 40% of the patients receiving T (p < 0.05), after 24 h in 69% (P) and 48% (T) (p < 0.05) and after 48 h in 74% (P) versus 58% (T) (p < 0.08) of the patients. No differences were observed regarding major bleeding, intracranial bleeding or nonhemorrhagic strokes. After nine months a reduction of combined death/myocardial infarction/target vessel revascularization could be observed in the tirofiban group ([T] 2.3% vs. [P] 13.04%, p < 0.05). CONCLUSIONS: Troponin T release occurs after successful intervention in 74% of the patients undergoing elective PCI after 48 h even after pretreatment with aspirin and clopidogrel. The GP IIb/IIIa receptor antagonist tirofiban is able to decrease the incidence of troponin release significantly in this patient population.
http://hdl.handle.net/10993/18379
10.1016/S0735-1097(02)02014-4
http://www.sciencedirect.com/science/article/pii/S0735109702020144#

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Limited access
Effect of additional temporary glycoprotein IIbIIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial)..pdfPublisher postprint130.88 kBRequest a copy

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.